A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms

Abstract Bacteriocins are ribosomally-synthesized antimicrobial peptides, showing great potential as novel treatment options for multidrug-resistant pathogens. In this study, we designed a novel hybrid bacteriocin, Hybrid 1 (H1), by combing the N-terminal part and the C-terminal part of the related...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christian Kranjec, Sofie S. Kristensen, Karolina T. Bartkiewicz, Mikkel Brønner, Jorunn P. Cavanagh, Aparna Srikantam, Geir Mathiesen, Dzung B. Diep
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4bb49ca80ceb456895b33b7ca266dcc3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4bb49ca80ceb456895b33b7ca266dcc3
record_format	dspace
spelling	oai:doaj.org-article:4bb49ca80ceb456895b33b7ca266dcc32021-12-02T16:15:07ZA bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms10.1038/s41598-021-93158-z2045-2322https://doaj.org/article/4bb49ca80ceb456895b33b7ca266dcc32021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93158-zhttps://doaj.org/toc/2045-2322Abstract Bacteriocins are ribosomally-synthesized antimicrobial peptides, showing great potential as novel treatment options for multidrug-resistant pathogens. In this study, we designed a novel hybrid bacteriocin, Hybrid 1 (H1), by combing the N-terminal part and the C-terminal part of the related bacteriocins enterocin K1 (K1) and enterocin EJ97 (EJ97), respectively. Like the parental bacteriocins, H1 used the membrane-bound protease RseP as receptor, however, it differed from the others in the inhibition spectrum. Most notably, H1 showed a superior antimicrobial effect towards Staphylococcus haemolyticus—an important nosocomial pathogen. To avoid strain-dependency, we further evaluated H1 against 27 clinical and commensal S. haemolyticus strains, with H1 indeed showing high activity towards all strains. To curtail the rise of resistant mutants and further explore the potential of H1 as a therapeutic agent, we designed a bacteriocin-based formulation where H1 was used in combination with the broad-spectrum bacteriocins micrococcin P1 and garvicin KS. Unlike the individual bacteriocins, the three-component combination was highly effective against planktonic cells and completely eradicated biofilm-associated S. haemolyticus cells in vitro. Most importantly, the formulation efficiently prevented development of resistant mutants as well. These findings indicate the potential of a bacteriocins-based formulation as a treatment option for S. haemolyticus.Christian KranjecSofie S. KristensenKarolina T. BartkiewiczMikkel BrønnerJorunn P. CavanaghAparna SrikantamGeir MathiesenDzung B. DiepNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Christian Kranjec Sofie S. Kristensen Karolina T. Bartkiewicz Mikkel Brønner Jorunn P. Cavanagh Aparna Srikantam Geir Mathiesen Dzung B. Diep A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms
description	Abstract Bacteriocins are ribosomally-synthesized antimicrobial peptides, showing great potential as novel treatment options for multidrug-resistant pathogens. In this study, we designed a novel hybrid bacteriocin, Hybrid 1 (H1), by combing the N-terminal part and the C-terminal part of the related bacteriocins enterocin K1 (K1) and enterocin EJ97 (EJ97), respectively. Like the parental bacteriocins, H1 used the membrane-bound protease RseP as receptor, however, it differed from the others in the inhibition spectrum. Most notably, H1 showed a superior antimicrobial effect towards Staphylococcus haemolyticus—an important nosocomial pathogen. To avoid strain-dependency, we further evaluated H1 against 27 clinical and commensal S. haemolyticus strains, with H1 indeed showing high activity towards all strains. To curtail the rise of resistant mutants and further explore the potential of H1 as a therapeutic agent, we designed a bacteriocin-based formulation where H1 was used in combination with the broad-spectrum bacteriocins micrococcin P1 and garvicin KS. Unlike the individual bacteriocins, the three-component combination was highly effective against planktonic cells and completely eradicated biofilm-associated S. haemolyticus cells in vitro. Most importantly, the formulation efficiently prevented development of resistant mutants as well. These findings indicate the potential of a bacteriocins-based formulation as a treatment option for S. haemolyticus.
format	article
author	Christian Kranjec Sofie S. Kristensen Karolina T. Bartkiewicz Mikkel Brønner Jorunn P. Cavanagh Aparna Srikantam Geir Mathiesen Dzung B. Diep
author_facet	Christian Kranjec Sofie S. Kristensen Karolina T. Bartkiewicz Mikkel Brønner Jorunn P. Cavanagh Aparna Srikantam Geir Mathiesen Dzung B. Diep
author_sort	Christian Kranjec
title	A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms
title_short	A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms
title_full	A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms
title_fullStr	A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms
title_full_unstemmed	A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms
title_sort	bacteriocin-based treatment option for staphylococcus haemolyticus biofilms
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4bb49ca80ceb456895b33b7ca266dcc3
work_keys_str_mv	AT christiankranjec abacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT sofieskristensen abacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT karolinatbartkiewicz abacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT mikkelbrønner abacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT jorunnpcavanagh abacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT aparnasrikantam abacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT geirmathiesen abacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT dzungbdiep abacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT christiankranjec bacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT sofieskristensen bacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT karolinatbartkiewicz bacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT mikkelbrønner bacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT jorunnpcavanagh bacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT aparnasrikantam bacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT geirmathiesen bacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms AT dzungbdiep bacteriocinbasedtreatmentoptionforstaphylococcushaemolyticusbiofilms
_version_	1718384288233160704

A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms

Ejemplares similares